Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 1/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 3/20 | 0.34 |
| ▸ | CNR2 | P34972 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KIF11 | P52732 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22096412 | 0.76 | KIF11 (0.44) | LMNAMAPTHTTKIF11 | |
| SCHEMBL22096311 | 0.76 | ACLY (0.35) | ACLYESR1CNR1CNR2LMNA | |
| SCHEMBL11922137 | 0.74 | GABRA1 (0.30) | — | |
| SCHEMBL25440558 | 0.71 | — | — | |
| SCHEMBL22147282 | 0.70 | PON1 (0.40) | ACLYESR1CNR1CNR2LMNA | |
| SCHEMBL26746359 | 0.70 | CYP1A1 (0.35) | ACLYESR1CNR1CNR2LMNA | |
| SCHEMBL20182530 | 0.70 | ACLY (0.33) | ACLYESR1CNR1CNR2 | |
| SCHEMBL20327695 | 0.69 | ACLY (0.32) | ACLY | |
| SCHEMBL18798721 | 0.69 | — | — | |
| SCHEMBL1755694 | 0.68 | DAO (0.44) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067673-A1 | MODIFIED NUCLEOSIDE OR NUCLEOTIDE | BGI SHENZHEN (CN) | 2024-02-29 | — | — | US | disclosed |
| US-10978255-B2 | Bichromic bipodal triphenylamine-based dyes with high photo-electron conversion at low light intensities | KOIVISTO BRYAN (CA) | 2021-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240067673-A1 | MODIFIED NUCLEOSIDE OR NUCLEOTIDE | NT5C3B, NT5E, NT5C2 | ACLY 2239/4885ESR1 3786/4885CNR1 4045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.